Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease
Authors
Keywords
-
Journal
SEMINARS IN NEPHROLOGY
Volume 43, Issue 3, Pages 151427
Publisher
Elsevier BV
Online
2023-10-18
DOI
10.1016/j.semnephrol.2023.151427
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo
- (2023) Katherine R. Tuttle et al. KIDNEY INTERNATIONAL
- Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
- (2022) Avivit Cahn et al. DIABETES CARE
- Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
- (2022) Katherine Tuttle et al. Clinical Journal of the American Society of Nephrology
- Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease
- (2022) Katherine R. Tuttle et al. KIDNEY INTERNATIONAL
- Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
- (2022) et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
- (2022) Suzanne V. Arnold et al. BMC Endocrine Disorders
- Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
- (2022) Peter Rossing et al. DIABETES CARE
- Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
- (2022) Ian H. de Boer et al. DIABETES CARE
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
- (2022) Peter Rossing et al. KIDNEY INTERNATIONAL
- SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
- (2022) Muthiah Vaduganathan et al. LANCET
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
- (2022) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Introduction and Methodology: Standards of Care in Diabetes—2023
- (2022) Nuha A. ElSayed et al. DIABETES CARE
- Empagliflozin in Patients with Chronic Kidney Disease
- (2022) NEW ENGLAND JOURNAL OF MEDICINE
- Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study
- (2021) Samantha T. Harris et al. DIABETES CARE
- Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program
- (2021) Tamara K. Young et al. DIABETOLOGIA
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
- (2021) Ahmed M. Shaman et al. CIRCULATION
- Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
- (2021) Peter Rossing et al. DIABETES OBESITY & METABOLISM
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
- (2021) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease
- (2021) Guanghong Jia et al. HYPERTENSION
- Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study
- (2020) Kåre I. Birkeland et al. DIABETES OBESITY & METABOLISM
- The tubular hypothesis of nephron filtration and diabetic kidney disease
- (2020) Volker Vallon et al. Nature Reviews Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
- (2020) Katherine R. Tuttle et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT
- (2020) Muhammad Abdul-Ghani et al. DIABETES CARE
- SGLT2 inhibitors may offer benefit beyond diabetes
- (2020) Amy Kang et al. Nature Reviews Nephrology
- Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
- (2020) Radica Z. Alicic et al. Nature Reviews Nephrology
- Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
- (2019) Radica Z. Alicic et al. DIABETES
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging
- (2019) Kengo Kidokoro et al. CIRCULATION
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c
- (2019) Christopher P. Cannon et al. CIRCULATION
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
- (2018) Silvio E. Inzucchi et al. CIRCULATION
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Back to the Future: Glomerular Hyperfiltration and the Diabetic Kidney
- (2016) Katherine R. Tuttle DIABETES
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metformin in Patients With Type 2 Diabetes and Kidney Disease
- (2014) Silvio E. Inzucchi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
- (2012) Caroline S Fox et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started